Corcept Therapeutics Incorporated
(CORT)Valuation Metrics
Market Cap
$9.70B
P/E Ratio
74.74
Forward P/E
29.24
PEG Ratio
0.61
Price/Book
8.48
Price/Sales
17.85
Financial Performance
Revenue (TTM)
$675.04M
EBITDA
$137.75M
EPS (TTM)
$1.23
Profit Margin
20.90%
Operating Margin
13.90%
Return on Equity
23.80%
Analyst Ratings
Dividends
Dividend Yield
N/A
Dividend Per Share
$None
Ex-Dividend Date
None
Metric | Q3 2024Sep 30, 2024 | Q2 2024Jun 30, 2024 | Q1 2024Mar 31, 2024 | Q3 2023Sep 30, 2023 | Q2 2023Jun 30, 2023 |
|---|---|---|---|---|---|
| Revenues | $182.55M | $163.80M | $146.81M | $123.60M | $117.72M |
| Cost of Revenue | $2.87M | $2.52M | $2.54M | $1.65M | $1.57M |
| Gross Profit | $179.68M | $161.27M | $144.27M | $121.96M | $116.14M |
| Operating Expenses | $133.08M | $125.68M | $114.77M | $90.78M | $86.56M |
| SG&A Expenses | $73.75M | $66.94M | $56.27M | $45.26M | $43.28M |
| R&D | $59.34M | $58.74M | $58.51M | $45.52M | $43.28M |
| Operating Income | $46.60M | $35.59M | $29.50M | $31.18M | $29.58M |
| Non-operating Income/Loss | $6.34M | $6.00M | $5.49M | $5.21M | $3.35M |
| Income Tax | $5.73M | $6.11M | $7.23M | $5.01M | $5.40M |
| Net Income | $47.21M | $35.49M | $27.76M | $31.38M | $27.53M |
| Basic EPS | $0.45 | $0.34 | $0.27 | $0.31 | $0.27 |
| Diluted EPS | $0.41 | $0.32 | $0.25 | $0.28 | $0.25 |
Recent News
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More
CORT and AXSM are in the spotlight this week following the announcement of study data.
Does Corcept ( CORT ) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag
The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.
Corcept Therapeutics Unusual Options Activity For April 01 - Corcept Therapeutics ( NASDAQ:CORT )
Investors with a lot of money to spend have taken a bearish stance on Corcept Therapeutics CORT. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian cancer meets the primary endpoint.